Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographics and clinical characteristics of 258 RA patients

From: The agreement between ultrasound-determined joint inflammation and clinical signs in patients with rheumatoid arthritis

Parameters Values
Age (years), mean ± SD 51.23 ± 13.74
Female, n (%) 215 (83.33)
Disease duration(months), median (IQR) 57 (14.75, 121.75)
Positive RF, n (%) 165 (73.01)
Positive ACPA, n (%) 153 (87.43)
TJC-22, median (IQR) 3 (1.6)
SJC-22, median (IQR) 2 (0.5)
ESR (mm/h), median (IQR) 29 (16.49)
CRP (mg/L), median (IQR) 9.24 (3.57, 27.60)
Patient’s global assessment (mm), median (IQR) 50 (30, 70)
Evaluator’s global assessment (mm), median (IQR) 40 (20, 60)
DAS28-ESR, mean ± SD 4.47 ± 1.62
DAS28-CRP, mean ± SD 3.99 ± 1.51
CDAI, median (IQR) 14 (8, 24)
SDAI, median (IQR) 15.38 (8.30, 26.83)
HAQ DI, median (IQR) 0.40 (0.10, 0.90)
Individual of csDMARD use
 Methotrexate, n (%) 160 (62.02)
 Hydroxychloroquine, n (%) 96 (37.21)
 Leflunomide, n (%) 70 (27.13)
 Sulfasalazine, n (%) 12 (4.65)
bDMARD use (%) 12 (4.65)
Number of DMARDs
 0, n (%) 52 (20.16)
 1, n (%) 84 (32.56)
 2, n (%) 93 (36.05)
 ≥ 3, n (%) 29 (11.24)
Glucocorticoid use (%)
 Oral glucocorticoid use, n (%) 41 (15.89)
 Oral glucocorticoid dose (mg/day), median(IQR) 10 (5.10) (prednisone equivalent)
 Recent intramuscular injection of glucocorticoid (within 14 days), n (%) 17 (6.59)
NSAIDs on demand, n (%) 23 (8.91)
  1. Abbreviations: RF rheumatoid factor, ACPA anti-citrullinated peptide antibody, TJC-22 tender joint count in bilateral wrists, MCPs and PIPs joints, SJC-22 swollen joint count in bilateral wrists, MCPs and PIPs joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28-ESR Disease Activity Score based on 28 joint count and ESR, DAS28-CRP Disease Activity Score based on 28 joint count and CRP, CDAI Clinical Disease Activity Index, SDAI Simplified Disease Activity Index, HAQ DI Health Assessment Questionnaire disability index, csDMARDs conventional synthetic disease-modified anti-rheumatic drugs, bDMARD biological disease-modified anti-rheumatic drugs, NSAIDs non-steroidal anti-inflammatory drugs